Joanna Robson1,2, Sarah Mackie3,4, Catherine Hill5,6. 1. Centre for Health and Clinical Research, University of the West of England, Bristol, UK. Jo.Robson@uwe.ac.uk. 2. Rheumatology Department, University Hospitals Bristol and Weston NHF Foundation Trust, Bristol, UK. Jo.Robson@uwe.ac.uk. 3. Vascular Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. 4. Rheumatology Department, Leeds Teaching Hospital NHS Trust, Chapel Allerton Hospital, Leeds, UK. 5. Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, South Australia, Australia. 6. Division of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Abstract
PURPOSE OF REVIEW: The goal of this paper is to review current and future uses of patient-reported outcomes in large vessel vasculitis. The large vessel vasculitides comprise Giant Cell Arteritis and Takayasu arteritis; both are types of systemic vasculitis which affect the larger blood vessels. Patient-reported outcomes (PROs) capture the impact of these diseases on health-related quality of life. RECENT FINDINGS: Generic PROs such as the SF-36 are currently used to compare HRQOL of people with GCA and TAK within clinical trials and observational studies and to make comparisons with the general population and HRQoL in other diseases. The development of a disease-specific PRO for GCA is currently underway. Beyond clinical trials, there is much interest in the use of PROs within routine clinical care, particularly E-PROs for remote use. Further work will be needed to complete the development of disease-specific PROs for people with large vessel vasculitis and to establish feasibility, acceptability, and utility of E-PROs.
PURPOSE OF REVIEW: The goal of this paper is to review current and future uses ofpatient-reported outcomes in large vessel vasculitis. The large vessel vasculitides comprise Giant Cell Arteritis and Takayasu arteritis; both are types ofsystemic vasculitis which affect the larger blood vessels. Patient-reported outcomes (PROs) capture the impact of these diseases on health-related quality of life. RECENT FINDINGS: Generic PROs such as the SF-36 are currently used to compare HRQOL ofpeople with GCA and TAK within clinical trials and observational studies and to make comparisons with the general population and HRQoL in other diseases. The development of a disease-specific PRO for GCA is currently underway. Beyond clinical trials, there is much interest in the use of PROs within routine clinical care, particularly E-PROs for remote use. Further work will be needed to complete the development of disease-specific PROs for people with large vessel vasculitis and to establish feasibility, acceptability, and utility ofE-PROs.
Authors: M J Kupersmith; R Speira; R Langer; M Richmond; M Peterson; H Speira; H Mitnick; S Paget Journal: J Neuroophthalmol Date: 2001-12 Impact factor: 3.042
Authors: Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel Journal: J Rheumatol Date: 2011-07 Impact factor: 4.666
Authors: Rachel J Black; Joanna C Robson; Susan M Goodman; Elizabeth Hoon; Lana Y H Lai; Lee S Simon; Eileen Harrison; Lorna Neill; Pam Richards; Linda M Nelsen; J Michael Nebesky; Sarah L Mackie; Catherine L Hill Journal: J Rheumatol Date: 2017-04-01 Impact factor: 4.666
Authors: Donald L Patrick; Laurie B Burke; John H Powers; Jane A Scott; Edwin P Rock; Sahar Dawisha; Robert O'Neill; Dianne L Kennedy Journal: Value Health Date: 2007 Nov-Dec Impact factor: 5.725
Authors: David B Hellmann; Misty L Uhlfelder; John H Stone; Mollie W Jenckes; Maria C Cid; Loic Guillevin; Larry Moreland; Paul F Dellaripa; Gary S Hoffman; Peter A Merkel; Robert Spiera; Lin Brown; José Hernández-Rodríguez; Haya R Rubin Journal: Arthritis Rheum Date: 2003-12-15
Authors: J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts Journal: Arthritis Rheum Date: 2013-01